Silibinin protects mice from T cell-dependent liver injury☆

Schumann, Johann; Prockl, Jennifer; Kiemer, Alexandra K.; Vollmar, Angelika M.; Bang, Renate; Tiegs, Gisa

doi:10.1016/s0168-8278(03)00239-3

Cited by 161 publications

(126 citation statements)

References 42 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…Recent studies have shown that silibinin has a strong antioxidant activity, increases cellular glutathione content, induces superoxide dismutase (SOD), antagonizes manganese-induced neurotoxicity in adult mice, and inhibits lipid peroxidation (Schumann et al, 2003). In addition, silibinin also possess anti-inflammatory (Min et al, 2007), growth-modulating and anti-carcinogenic effects (Chu et al, 2004).…”

Section: Discussionmentioning

confidence: 99%

Silibinin: A novel inhibitor of Aβ aggregation

Yin

Liu

Ji³

et al. 2011

Neurochemistry International

117

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Silibinin: A novel inhibitor of Aβ aggregation

Yin

Liu

Ji³

et al. 2011

Neurochemistry International

117

View full text Add to dashboard Cite

“…The oral administration at the dosage of 100 mg/kg attenuated NO production by peritoneal macrophages in lipopolysaccharide (LPS)-treated mice. Silymarin, also concentration-dependent, suppressed the LPS-induced production of NO in isolated (Schümann et al, 2003). The authors tested silibinin in the mouse model of concanavalin A (ConA)-induced, T cell-dependent hepatitis.…”

Section: Anti-inflammatory and Immuno-modulation Activitymentioning

confidence: 99%

Milk thistle in liver diseases: past, present, future

Abenavoli

Capasso²,

Milić

et al. 2010

Phytotherapy Research

489

350

View full text Add to dashboard Cite

Silybum marianum or milk thistle (MT) is the most well‐researched plant in the treatment of liver disease. The active complex of MT is a lipophilic extract from the seeds of the plant and is composed of three isomer flavonolignans (silybin, silydianin, and silychristin) collectively known as silymarin. Silybin is a component with the greatest degree of biological activity and makes up 50% to 70% of silymarin. Silymarin is found in the entire plant but it is concentrated in the fruit and seeds. Silymarin acts as an antioxidant by reducing free radical production and lipid peroxidation, has antifibrotic activity and may act as a toxin blockade agent by inhibiting binding of toxins to the hepatocyte cell membrane receptors. In animals, silymarin reduces liver injury caused by acetaminophen, carbon tetrachloride, radiation, iron overload, phenylhydrazine, alcohol, cold ischaemia and Amanita phalloides. Silymarin has been used to treat alcoholic liver disease, acute and chronic viral hepatitis and toxin‐induced liver diseases. Copyright © 2010 John Wiley & Sons, Ltd.

show abstract

“…Although being used in clinical practice worldwide, its therapeutic efficacy has been questioned for years. Potent scavenging properties have been demonstrated in vitro and in vivo, in different hepatic and non-hepatic cells [18,19]; and strong evidences for silibinin therapeutic efficacy have been reported in different types of experimental liver injury [20][21][22].…”

Section: Introductionmentioning

confidence: 99%

Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis

Salamone¹,

Galvano²,

Marino³

et al. 2012

Digestive and Liver Disease

View full text Add to dashboard Cite

a b s t r a c tBackground: Nonalcoholic fatty liver disease is a chronic metabolic disorder with significant impact on cardiovascular and liver mortality. Aims: In this study, we examined the effects of silibinin on liver and myocardium injury in an experimental model of nonalcoholic fatty liver disease. Methods: A four-week daily dose of silibinin (20 mg/kg i.p.) was administrated to db/db mice fed a methionine-choline deficient diet. Hepatic and myocardial histology, oxidative stress and inflammatory cytokines were evaluated. Results: Silibinin administration decreased HOMA-IR, serum ALT and markedly improved hepatic and myocardial damage. Silibinin reduced isoprostanes, 8-deoxyguanosine and nitrites/nitrates in the liver and in the heart of db/db fed the methionine-choline deficient diet, whereas glutathione levels were restored to lean mice levels in both tissues. Consistently, liver mitochondrial respiratory chain activity was significantly impaired in untreated mice and was completely restored in silibinin-treated animals. TNF-␣ was increased whereas IL-6 was decreased both in the liver and heart of db/db fed methionine-choline deficient diet. Silibinin reversed heart TNF-␣ and IL-6 expression to control mice levels. Indeed, liver JNK phosphorylation was reduced to control levels in treated animals. Conclusions: This study demonstrates a combined effectiveness of silibinin on improving liver and myocardial injury in experimental nonalcoholic fatty liver disease.

show abstract

Silibinin protects mice from T cell-dependent liver injury☆

Cited by 161 publications

References 42 publications

Silibinin: A novel inhibitor of Aβ aggregation

Silibinin: A novel inhibitor of Aβ aggregation

Milk thistle in liver diseases: past, present, future

Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis

Contact Info

Product

Resources

About